Skip to main content

Table 3 Results of subgroup analyses on prognostic effects of GC patients

From: Log odds of positive lymph nodes as a novel prognostic predictor for gastric cancer: a systematic review and meta-analysis

Comparisons (vs LODDS0)

OS

No. of studies

HR (95% CI)

Heterogeneity

Egger’s Test p Value

I2 (%)

P

TOTAL studies

 LODDS1

10

1.62 (1.42, 1.85)

63.5%

0.003

0.608

 LODDS2

11

2.47 (2.02, 3.03)

86.2%

 < 0.001

0.799

 LODDS3

11

3.15 (2.50, 3.97)

92.1%

 < 0.001

0.943

 LODDS4

11

4.55 (3.29, 6.29)

96.6%

 < 0.001

0.216

Yearc

 ≥ Median

  LODDS1

5

1.50 (1.23, 1.82)

79.4%

0.001

 

  LODDS2

6

2.41 (1.88, 3.09)

83.3%

 < 0.001

 

  LODDS3

6

2.95 (2.04, 4.27)

95.7%

 < 0.001

 

  LODDS4

6

5.82 (4.30, 7.87)

90.8%

 < 0.001

 

 < Median

  LODDS1

5

1.78 (1.56, 2.04)

0.0%

0.714

 

  LODDS2

5

2.58 (1.76, 3.80)

89.3%

 < 0.001

 

  LODDS3

5

3.38 (2.80, 4.09)

53.9%

0.07

 

  LODDS4

5

3.32 (2.11, 5.23)

95.9%

 < 0.001

 

Country

 East Asia

  LODDS1

8

1.65 (1.49, 1.84)

39.9%

0.113

 

  LODDS2

8

2.56 (2.15, 3.05)

77.5%

 < 0.001

 

  LODDS3

8

3.33 (2.86, 3.87)

77.8%

 < 0.001

 

  LODDS4

8

4.89 (3.90, 6.14)

90.6%

 < 0.001

 

 non-East Asia

  LODDS1

2

1.57 (0.69, 3.57)

86.7%

0.006

 

  LODDS2

3

2.21 (1.04, 4.71)

88.7%

 < 0.001

 

  LODDS3

3

2.79 (1.21, 6.44)

90.2%

 < 0.001

 

  LODDS4

3

3.60 (1.55, 8.32)

90.1%

 < 0.001

 

Patient no.d

 ≥ Median

  LODDS1

5

1.60 (1.42, 1.81)

56.0%

0.059

 

  LODDS2

6

2.47 (2.01, 3.04)

83.2%

 < 0.001

 

  LODDS3

6

3.23 (2.71, 3.85)

83.7%

 < 0.001

 

  LODDS4

6

4.05 (2.63, 6.24)

98.0%

 < 0.001

 

 < Median

  LODDS1

5

1.76 (1.24, 2.49)

73.7%

0.004

 

  LODDS2

5

2.50 (1.55, 4.03)

87.0%

 < 0.001

 

  LODDS3

5

3.17 (1.77, 5.68)

92.0%

 < 0.001

 

  LODDS4

5

5.43 (3.04, 9.69)

91.0%

 < 0.001

 

Neoadjuvant therapy

 No

  LODDS1

3

1.85 (1.64, 2.07)

0.0%

0.381

 

  LODDS2

5

3.04 (2.58, 3.58)

29.2%

0.227

 

  LODDS3

4

4.03 (3.66, 4.43)

0.0%

0.975

 

  LODDS4

5

6.36 (4.50, 8.99)

81.3%

 < 0.001

 

 All

  LODDS1

3

1.38 (1.05, 1.82)

67.1%

0.048

 

  LODDS2

3

2.00 (1.39, 2.88)

87.5%

 < 0.001

 

  LODDS3

3

2.47 (1.42, 4.30)

95.6%

 < 0.001

 

  LODDS4

2

2.41 (1.34, 4.36)

97.5%

 < 0.001

 

 UKN

  LODDS1

4

1.59 (1.35, 1.89)

49.0%

0.118

 

  LODDS2

3

2.26 (1.54, 3.31)

83.0%

0.003

 

  LODDS3

4

3.07 (2.53, 3.71)

66.2%

 < 0.001

 

  LODDS4

4

4.29 (3.17, 5.82)

86.4%

 < 0.001

 
  1. Abbreviations: GC Gastric cancer, HR hazard ratio, OS overall survival, DFS disease-free survival, LODDS log odds of positive lymph nodes, UKN Unknown
  2. aP-value for estimates of HR
  3. bP-value for heterogeneity
  4. cThe median year of LODDS1, LODDS2, LODDS3, and LODDS4 was 2015, 2016, 2015, and 2016, respectively
  5. dThe median patient number of LODDS1, LODDS2, LODDS3, and LODDS4 was 172, 160, 142, and 132, respectively
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us